From DCAT Value Chain Insights (VCI)
Biogen has appointed Jean-Paul Kress, MD, as executive vice president and president, international, and head of Global Therapeutic Operations, effective June 19, 2017.
Dr. Kress will have direct responsibility for worldwide commercial operations outside the US and will also oversee the Rare and Specialty Disease Asset teams. Dr. Kress will report directly to Chief Executive Officer Michel Vounatsos and be a member of Biogen’s Executive Committee.
Prior to his appointment, Dr. Kress was most recently senior vice president, head of North America at Sanofi Genzyme, where he oversaw the multiple sclerosis, oncology, and immunology business units in the US and Canada.
Thank you for reading DCAT Value Chain Insights (VCI), an information resource from the
Drug, Chemical & Associated Technologies Association (DCAT).
Learn more and sign up to receive a complimentary subscription